FDA panel approves expanded use of peptides in compounding pharmacies, raising concerns about prescription surge in billion-dollar industry.Unusual Whales·2 days ago, 05:24 PMIXJ+0.60%BBH-0.23%
Thermo Fisher Rated Buy on Broad-Based Recovery, Conservative Guidance, and Attractive Valuation Versus PeersTip Ranks·Jul 24 at 02:15 AMTMO-0.71%
12:26 ETNASDAQ: ERAS CLASS ACTION NOTICE: Berger Montague Encourages Erasca, Inc. (NASDAQ: ERAS) Investors to Inquire About a Securities Fraud Class Actionprnewswire·Jul 22 at 11:26 AMERAS-1.19%
Fed Chair Kevin Warsh faces a committee where 9 of 19 members are signaling higher interest rates this yearMSN·4 hours ago
16:26 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSSprnewswire·Jul 21 at 03:28 PMERAS-1.19%RVMD+0.25%
15:31 ETErasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuitprnewswire·2 days ago, 02:31 PMERAS-1.19%
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?Motley Fool·Jul 19 at 08:05 PMABBV+0.95%APGE+1.00%
Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Moderate Buy" from AnalystsMarket Beat·Jul 20 at 03:29 AMERAS-1.19%
Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallStPR Newswire·Jul 23 at 09:07 AMERAS-1.19%
President sets import tariffs after 2-year grace period for medicinesFOX Business·Jul 21 at 09:11 PMBIS+1.21%SBIO-0.88%
